FTC Hearing On IP Policy: Patent Eligibility Requirements Are Top Industry Concern
Executive Summary
Supreme Court decisions on subject matter patentability have discouraged investments, panelists tell FTC; BIO says biotech companies may look outside patent system.
You may also be interested in...
I-MAK Defends ‘Patent Thicket’ Claims In Response To Thom Tillis Letter
The Initiative for Medicines, Access & Knowledge has responded to criticisms leveled by North Carolina senator Thom Tillis at a report it published in 2018. The report accuses pharmaceutical firms of using patent thickets to suppress generic and biosimilar competition in the US market.
US FDA, PTO Pulled Into Debate Over Patents And Drug Pricing
Senator Tillis requests the two agencies conduct an independent analysis of I-MAK data and the ‘false narrative’ that patents are to blame for high drug prices.
US PTO's Patent Eligibility Guidance Draws Industry Plaudits, Request For More Specifics
BIO, PhRMA, Novartis, Amgen, and Genentech suggest revisions to guidance on hot-button issue of subject matter patent eligiblity; patent owners group says 'best approach' is to enact legislation to restore patent eligibility law.